Should I buy or sell IDEXX Laboratories stock right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for IDEXX Laboratories in the last year. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" IDXX shares. View IDXX analyst ratings or view top-rated stocks .

What is IDEXX Laboratories' stock price target for 2024?

8 brokers have issued 12-month price targets for IDEXX Laboratories' stock. Their IDXX share price targets range from $460.00 to $610.00. On average, they anticipate the company's stock price to reach $554.88 in the next twelve months. This suggests a possible upside of 4.4% from the stock's current price. View analysts price targets for IDXX or view top-rated stocks among Wall Street analysts .

How have IDXX shares performed in 2023?

IDEXX Laboratories' stock was trading at $407.96 at the beginning of 2023. Since then, IDXX stock has increased by 30.2% and is now trading at $531.35. View the best growth stocks for 2023 here .

When is IDEXX Laboratories' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 5th 2024. View our IDXX earnings forecast .

How were IDEXX Laboratories' earnings last quarter?

IDEXX Laboratories, Inc. (NASDAQ:IDXX) announced its quarterly earnings data on Wednesday, November, 1st. The company reported $2.53 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.37 by $0.16. The business had revenue of $915.53 million for the quarter, compared to analysts' expectations of $926.88 million. IDEXX Laboratories had a net margin of 22.93% and a trailing twelve-month return on equity of 85.68%. The business's revenue was up 8.8% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.15 EPS. Read the conference call transcript .

What ETFs hold IDEXX Laboratories' stock?

ETFs with the largest weight of IDEXX Laboratories (NASDAQ:IDXX) stock in their portfolio include ProShares Pet Care ETF (PAWZ) , Sterling Capital Focus Equity ETF (LCG) , Invesco Dorsey Wright Healthcare Momentum ETF (PTH) , ProShares Nasdaq-100 Dorsey Wright Momentum ETF (QQQA) , First Trust Water ETF (FIW) , iShares U.S. Medical Devices ETF (IHI) , Neuberger Berman Disrupters ETF (NBDS) and Putnam Sustainable Future ETF (PFUT) .

What is Jay Mazelsky's approval rating as IDEXX Laboratories' CEO?

40 employees have rated IDEXX Laboratories Chief Executive Officer Jay Mazelsky on Glassdoor.com . Jay Mazelsky has an approval rating of 69% among the company's employees.

What other stocks do shareholders of IDEXX Laboratories own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IDEXX Laboratories investors own include NVIDIA (NVDA) , Netflix (NFLX) , PayPal (PYPL) , Mastercard (MA) , Adobe (ADBE) , Tesla (TSLA) , Alibaba Group (BABA) , Block (SQ) , Walt Disney (DIS) and Shopify (SHOP) .

Who are IDEXX Laboratories' major shareholders?

IDEXX Laboratories' stock is owned by many different retail and institutional investors. Top institutional investors include Bamco Inc. NY (2.81%), Invesco Ltd. (1.47%), Blair William & Co. IL (1.44%), Brown Advisory Inc. (1.40%), Morgan Stanley (1.28%) and Northern Trust Corp (1.11%). Insiders that own company stock include Brian P Mckeon, Brian P Mckeon , Daniel M Junius , Giovani Twigge , James F Polewaczyk, James F Polewaczyk , Jonathan Jay Mazelsky , Jonathan W Ayers , Kathy V Turner , Kathy V Turner , M Anne Szostak , Michael Lane , Nimrata Hunt , Rebecca M Henderson and Sophie V Vandebroek . View institutional ownership trends .

How do I buy shares of IDEXX Laboratories?

Shares of IDXX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

IDEXX Laboratories Stock Price, News & Analysis (NASDAQ:IDXX)

$531.35

+8.27 (+1.58%)

(As of 12/8/2023 ET)

Compare

Today's Range: $519.17
▼
$532.41
50-Day Range: $391.37
▼
$531.35
52-Week Range: $372.50
▼
$564.73

Volume: 540,491 shs
Average Volume: 479,798 shs
Market Capitalization: $44.13 billion

P/E Ratio: 54.22
Dividend Yield: N/A
Price Target: $554.88

IDEXX Laboratories MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.75 Rating Score
Upside/Downside: 4.4% Upside
$554.88 Price Target
Short Interest: Bearish
3.37% of Float Sold Short
Dividend Strength: N/A
Sustainability: -2.09
Upright™ Environmental Score
News Sentiment: 0.70
Based on 18 Articles This Week
Insider Trading: Selling Shares
$9.73 M Sold Last Quarter
Proj. Earnings Growth: 11.68%
From $9.85 to $11.00 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.34 out of 5 stars

Medical Sector

222nd out of 944 stocks

Diagnostic Substances Industry

3rd out of 13 stocks

2.4

Analyst's Opinion

Consensus Rating
IDEXX Laboratories has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 6 buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $554.88, IDEXX Laboratories has a forecasted upside of 4.4% from its current price of $531.35.
Amount of Analyst Coverage
IDEXX Laboratories has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.0

Short Interest

Percentage of Shares Shorted
3.37% of the float of IDEXX Laboratories has been sold short.
Short Interest Ratio / Days to Cover
IDEXX Laboratories has a short interest ratio ("days to cover") of 5.7.
Change versus previous month
Short interest in IDEXX Laboratories has recently increased by 0.73%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
IDEXX Laboratories does not currently pay a dividend.
Dividend Growth
IDEXX Laboratories does not have a long track record of dividend growth.

3.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
IDEXX Laboratories has received a 46.03% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Urine analyzers", "Biochemical assay kits", and "Veterinary laboratories for pets" products. See details.
Environmental Sustainability
The Environmental Impact score for IDEXX Laboratories is -2.09.

3.2

News and Social Media Coverage

News Sentiment
IDEXX Laboratories has a news sentiment score of 0.70. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 18 news articles for IDEXX Laboratories this week, compared to 7 articles on an average week.
Search Interest
Only 7 people have searched for IDXX on MarketBeat in the last 30 days. This is a decrease of -42% compared to the previous 30 days.
MarketBeat Follows
8 people have added IDEXX Laboratories to their MarketBeat watchlist in the last 30 days. This is an increase of 167% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, IDEXX Laboratories insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $9,728,569.00 in company stock.
Percentage Held by Insiders
Only 2.11% of the stock of IDEXX Laboratories is held by insiders.
Percentage Held by Institutions
86.85% of the stock of IDEXX Laboratories is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

2.5

Earnings and Valuation

Earnings Growth
Earnings for IDEXX Laboratories are expected to grow by 11.68% in the coming year, from $9.85 to $11.00 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of IDEXX Laboratories is 54.22, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 108.81.
Price to Earnings Ratio vs. Sector
The P/E ratio of IDEXX Laboratories is 54.22, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 85.94.
Price to Earnings Growth Ratio
IDEXX Laboratories has a PEG Ratio of 2.95. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
IDEXX Laboratories has a P/B Ratio of 72.29. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About IDEXX Laboratories Stock (NASDAQ:IDXX)

IDEXX Laboratories, Inc. develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It also provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments, and services for biomedical research community. In addition, the company offers diagnostic and health-monitoring products for livestock, poultry, and dairy products that test water for various microbiological contaminants; point-of-care electrolytes and blood gas analyzers; OPTI SARS-CoV-2 RT-PCR test kit for human COVID-19 testing; in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, and coagulation analyzers; and SNAP rapid assays test kits. Further, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; and veterinary software and services for independent veterinary clinics and corporate groups. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.

IDXX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

IDXX Stock News Headlines

December 9, 2023 | finance.yahoo.com

Insider Sell: Executive Vice President James Polewaczyk Sells Shares of IDEXX Laboratories Inc

December 9, 2023 | americanbankingnews.com

IDEXX Laboratories (NASDAQ:IDXX) Upgraded to "Buy" by StockNews.com

December 9, 2023 | Wealthpress (Ad)

Trading Experts Call It “The Perfect Tesla Trade”

Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.

December 9, 2023 | americanbankingnews.com

IDEXX Laboratories (NASDAQ:IDXX) Receives New Coverage from Analysts at BNP Paribas

December 8, 2023 | americanbankingnews.com

Jonathan Jay Mazelsky Sells 7,128 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) Stock

December 8, 2023 | finance.yahoo.com

Insider Sell: President and CEO Jonathan Mazelsky Sells Shares of IDEXX Laboratories Inc (IDXX)

December 7, 2023 | benzinga.com

$1000 Invested In This Stock 10 Years Ago Would Be Worth $10,000 Today

December 7, 2023 | finance.yahoo.com

IDEXX Laboratories Schedules Two Institutional Investor Events

December 9, 2023 | Wealthpress (Ad)

Trading Experts Call It “The Perfect Tesla Trade”

December 6, 2023 | finance.yahoo.com

IDEXX Laboratories Stock Earns IBD Stock Rating Upgrade

December 4, 2023 | realmoney.thestreet.com

Idexx Laboratories upgraded to Buy from Neutral at Cleveland Research

December 1, 2023 | finance.yahoo.com

Idexx (IDXX) Up 11.1% Since Last Earnings Report: Can It Continue?

November 30, 2023 | americanbankingnews.com

IDEXX Laboratories (NASDAQ:IDXX) Upgraded at StockNews.com

November 16, 2023 | finance.yahoo.com

ALC or IDXX: Which Is the Better Value Stock Right Now?

November 16, 2023 | finance.yahoo.com

IDEXX Laboratories (IDXX) Declined on Weak Clinical Visits Across the Industry

November 11, 2023 | finance.yahoo.com

IDEXX Laboratories (IDXX) Fell on Investors’ Concerns

November 11, 2023 | finance.yahoo.com

Investors in IDEXX Laboratories (NASDAQ:IDXX) have seen solid returns of 113% over the past five years

November 9, 2023 | benzinga.com

IDEXX Laboratories Executive Vice President Acquires 1,728 Shares After Exercising Company Stock Options

November 7, 2023 | morningstar.com

IDEXX Laboratories Inc IDXX

November 7, 2023 | finance.yahoo.com

IDEXX Laboratories Insiders Sold US$4.5m Of Shares Suggesting Hesitancy

November 6, 2023 | finance.yahoo.com

IDXX Jan 2024 380.000 put

November 3, 2023 | markets.businessinsider.com

5 Analysts Have This to Say About IDEXX Laboratories

November 3, 2023 | finance.yahoo.com

IDEXX Laboratories, Inc.'s (NASDAQ:IDXX) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?

November 2, 2023 | finance.yahoo.com

IDEXX Laboratories, Inc. (NASDAQ:IDXX) Q3 2023 Earnings Call Transcript

November 2, 2023 | finance.yahoo.com

Compared to Estimates, Idexx (IDXX) Q3 Earnings: A Look at Key Metrics

November 2, 2023 | finance.yahoo.com

Q3 2023 IDEXX Laboratories Inc Earnings Call

November 2, 2023 | finance.yahoo.com

The IDEXX Laboratories Inc (IDXX) Company: A Short SWOT Analysis

See More Headlines

Receive IDXX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IDEXX Laboratories and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/01/2023
Today: 12/09/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 2/05/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Diagnostic substances
Sub-Industry: Health Care Equipment
Sector: Medical
Current Symbol: NASDAQ:IDXX
CUSIP: 45168D10
CIK: 874716
Web: www.idexx.com
Phone: (207) 556-0300
Fax: 207-556-4346
Employees: 10,780
Year Founded: 1983

Price Target and Rating

Average Stock Price Target: $554.88
High Stock Price Target: $610.00
Low Stock Price Target: $460.00
Potential Upside/Downside: +4.4%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.75
Research Coverage: 8 Analysts

Profitability

EPS (Most Recent Fiscal Year): $9.80
Trailing P/E Ratio: 54.22
Forward P/E Ratio: 53.94
P/E Growth: 2.95
Net Income: $679.09 million
Net Margins: 22.93%
Pretax Margin: 28.84%
Return on Equity: 85.68%
Return on Assets: 28.59%

Debt

Debt-to-Equity Ratio: 0.48
Current Ratio: 1.43
Quick Ratio: 1.02

Sales & Book Value

Annual Sales: $3.37 billion
Price / Sales: 13.10
Cash Flow: $9.70 per share
Price / Cash Flow: 54.77
Book Value: $7.35 per share
Price / Book: 72.29

Miscellaneous

Outstanding Shares: 83,050,000
Free Float: 81,300,000
Market Cap: $44.13 billion
Optionable: Optionable
Beta: 1.23

Social Links

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Mr. Jonathan J. Mazelsky (Age 62)
President, CEO & Director
Comp: $2.04M
Mr. Brian P. McKeon (Age 61)
CFO, Executive VP & Treasurer
Comp: $1.06M
Mr. James F. Polewaczyk (Age 59)
Executive VP & Chief Commercial Officer
Comp: $889.99k
Mr. Michael J. Lane (Age 55)
Executive VP and GM of Reference Laboratories & Information Technology
Comp: $891.1k
Dr. Nimrata Khatra Hunt P.E. (Age 55)
Ph.D., Executive Vice President of Strategy, Sector Development & Global Operations
Comp: $887.77k
Mr. John Hart
Senior Vice President of Global Operations
Mr. Jeffery D. Chadbourne (Age 47)
Senior Director of Accounting & Financial Reporting
Dr. Martin Smith Ph.D. (Age 55)
Executive VP & CTO
Mr. Ken Grady
Senior VP & Chief Information Officer
Ms. Sharon E. Underberg (Age 62)
Executive VP, General Counsel, & Corporate Secretary
Comp: $881.05k

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

Should I Buy IDEXX Laboratories Stock? IDXX Pros and Cons Explained

These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of IDEXX Laboratories was last updated on Sunday, December 3, 2023 at 5:09 PM.

Pros

Here are some ways that investors could benefit from investing in IDEXX Laboratories, Inc.:

Strong presence in multiple markets: IDEXX Laboratories operates in the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide, providing a diversified revenue stream.
Companion Animal Group segment: The company's Companion Animal Group segment offers point-of-care veterinary diagnostic products, veterinary reference laboratory diagnostic services, and practice management systems for veterinarians, which are in high demand and contribute to the company's growth.
Innovation in diagnostic products: IDEXX Laboratories develops and manufactures a wide range of diagnostic products, including rapid assay test kits, analyzers, and testing instruments. The company's continuous innovation in this area keeps it competitive in the market.
Expansion into human COVID-19 testing: IDEXX Laboratories has developed the OPTI SARS-CoV-2 RT-PCR test kit for human COVID-19 testing. This expansion into the human testing market presents a new growth opportunity for the company.
Strong distribution network: The company markets its products through various channels, including marketing, customer service, sales, and technical service groups, as well as independent distributors and resellers. This extensive distribution network helps IDEXX Laboratories reach a wide customer base.

Cons

Investors should be bearish about investing in IDEXX Laboratories, Inc. for these reasons:

Competition in the market: IDEXX Laboratories operates in a highly competitive market, facing competition from other companies in the diagnostics and research industry. This competition could potentially impact the company's market share and profitability.
Regulatory challenges: As a healthcare equipment company, IDEXX Laboratories is subject to various regulations and compliance requirements. Changes in regulations or failure to comply with existing regulations could have a negative impact on the company's operations and financial performance.
Market volatility: The stock market can be volatile, and fluctuations in the market can affect the stock price of IDEXX Laboratories. Investors should be aware of the potential risks associated with investing in a volatile market.
Dependency on veterinary industry: IDEXX Laboratories heavily relies on the veterinary industry for its revenue. Any downturn or disruption in the veterinary industry could have a significant impact on the company's financial performance.
Potential impact of COVID-19: The ongoing COVID-19 pandemic has created uncertainties in the global economy and could potentially impact IDEXX Laboratories' business operations. Investors should consider the potential risks and challenges posed by the pandemic.

IDXX Stock Analysis - Frequently Asked Questions

Should I buy or sell IDEXX Laboratories stock right now?: 8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for IDEXX Laboratories in the last year. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" IDXX shares.
View IDXX analyst ratings or view top-rated stocks.
What is IDEXX Laboratories' stock price target for 2024?: 8 brokers have issued 12-month price targets for IDEXX Laboratories' stock. Their IDXX share price targets range from $460.00 to $610.00. On average, they anticipate the company's stock price to reach $554.88 in the next twelve months. This suggests a possible upside of 4.4% from the stock's current price.
View analysts price targets for IDXX or view top-rated stocks among Wall Street analysts.
How have IDXX shares performed in 2023?: IDEXX Laboratories' stock was trading at $407.96 at the beginning of 2023. Since then, IDXX stock has increased by 30.2% and is now trading at $531.35.
View the best growth stocks for 2023 here.
When is IDEXX Laboratories' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, February 5th 2024.
View our IDXX earnings forecast.
How were IDEXX Laboratories' earnings last quarter?: IDEXX Laboratories, Inc. (NASDAQ:IDXX) announced its quarterly earnings data on Wednesday, November, 1st. The company reported $2.53 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.37 by $0.16. The business had revenue of $915.53 million for the quarter, compared to analysts' expectations of $926.88 million. IDEXX Laboratories had a net margin of 22.93% and a trailing twelve-month return on equity of 85.68%. The business's revenue was up 8.8% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.15 EPS.
Read the conference call transcript.
What ETFs hold IDEXX Laboratories' stock?: ETFs with the largest weight of IDEXX Laboratories (NASDAQ:IDXX) stock in their portfolio include ProShares Pet Care ETF (PAWZ), Sterling Capital Focus Equity ETF (LCG), Invesco Dorsey Wright Healthcare Momentum ETF (PTH), ProShares Nasdaq-100 Dorsey Wright Momentum ETF (QQQA), First Trust Water ETF (FIW), iShares U.S. Medical Devices ETF (IHI), Neuberger Berman Disrupters ETF (NBDS) and Putnam Sustainable Future ETF (PFUT).

What is Jay Mazelsky's approval rating as IDEXX Laboratories' CEO?: 40 employees have rated IDEXX Laboratories Chief Executive Officer Jay Mazelsky on Glassdoor.com. Jay Mazelsky has an approval rating of 69% among the company's employees.
What other stocks do shareholders of IDEXX Laboratories own?: Based on aggregate information from My MarketBeat watchlists, some companies that other IDEXX Laboratories investors own include NVIDIA (NVDA), Netflix (NFLX), PayPal (PYPL), Mastercard (MA), Adobe (ADBE), Tesla (TSLA), Alibaba Group (BABA), Block (SQ), Walt Disney (DIS) and Shopify (SHOP).
Who are IDEXX Laboratories' major shareholders?: IDEXX Laboratories' stock is owned by many different retail and institutional investors. Top institutional investors include Bamco Inc. NY (2.81%), Invesco Ltd. (1.47%), Blair William & Co. IL (1.44%), Brown Advisory Inc. (1.40%), Morgan Stanley (1.28%) and Northern Trust Corp (1.11%). Insiders that own company stock include Brian P Mckeon, Brian P Mckeon, Daniel M Junius, Giovani Twigge, James F Polewaczyk, James F Polewaczyk, Jonathan Jay Mazelsky, Jonathan W Ayers, Kathy V Turner, Kathy V Turner, M Anne Szostak, Michael Lane, Nimrata Hunt, Rebecca M Henderson and Sophie V Vandebroek.
View institutional ownership trends.
How do I buy shares of IDEXX Laboratories?: Shares of IDXX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:IDXX) was last updated on 12/9/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

IDEXX Laboratories Stock Price, News & Analysis (NASDAQ:IDXX)

IDEXX Laboratories MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About IDEXX Laboratories Stock (NASDAQ:IDXX)

IDXX Stock Price History

IDXX Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

Should I Buy IDEXX Laboratories Stock? IDXX Pros and Cons Explained

Pros

Cons

IDXX Stock Analysis - Frequently Asked Questions

Overall MarketRank^™